Is eucrisa a biologic?

What is Eucrisa?

Eucrisa, also known as crisaborole, is a topical ointment used to treat moderate to severe atopic dermatitis (eczema) in adults and children 2 years of age and older [1]. It is a nonsteroidal, small molecule that works by reducing inflammation and inhibiting the production of pro-inflammatory cytokines.

Is Eucrisa a Biologic?

No, Eucrisa is not a biologic. While it targets a specific protein, the interleukin-4 receptor-alpha subunit, it is not derived from living organisms or produced through recombinant DNA technology, which are characteristics of biologics.

According to DrugPatentWatch.com, Eucrisa's patent [US 9149583 B2] was granted in 2015 [2]. As a non-biologic, smaller molecule, Eucrisa's patent does not fall under the complex biologic regulatory pathway.

Comparison to Biologics:

To provide context, biologics are large molecules produced through living organisms or recombinant DNA technology. They are often injected or infused to treat various diseases, including autoimmune disorders and cancers. Biologics can have complex mechanisms of action and may require special storage and handling. Eucrisa, being a small molecule, differs significantly in its composition, administration, and regulation.

Regulatory and Patent Considerations:

As a non-biologic, Eucrisa's development and approval process were governed by standard small molecule regulations. This distinction also impacts how pharmaceutical companies market and price their products.

Patent Expiration:

The patent expiration for Eucrisa is expected to occur in 2025, which may enable the development of generic alternatives [3].

Sources:

[1] Crisaborole (Eucrisa): MedlinePlus.
[2] DrugPatentWatch.com. Crisaborole (Eucrisa) Patent: US 9149583 B2.
[3] Patent expiration for Eucrisa: DrugPatentWatch.com.